Last reviewed · How we verify
ADX-914
ADX-914 is a monoclonal antibody targeting CD47.
ADX-914 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | ADX-914 |
|---|---|
| Sponsor | Q32 Bio Inc. |
| Drug class | CD47 inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to CD47, ADX-914 prevents tumor cells from evading immune detection, allowing the immune system to recognize and attack cancer cells. This mechanism is thought to enhance anti-tumor immune responses.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (PHASE2)
- Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (PHASE2)
- Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADX-914 CI brief — competitive landscape report
- ADX-914 updates RSS · CI watch RSS
- Q32 Bio Inc. portfolio CI